HEMLIBRA is indicated for routine prophylaxis in adult and pediatric patients (newborn and older) with congenital hemophilia A (Factor VIII deficiency), regardless of inhibitor status.

1. Loading Dose: 3 mg/kg subcutaneously once weekly for the first 4 weeks.

2. Maintenance Dose: Choose one of the following regimens:

1.5 mg/kg once weekly, or

3 mg/kg once every two weeks, or

6 mg/kg once every four weeks.

3. Discontinue prophylactic bypassing agents one day prior to initiating HEMLIBRA.

4. Factor VIII prophylaxis may be continued during the first week of HEMLIBRA therapy.